Neurological Panel

Molecular Test Requisition    Specimen Information    Billing Information    Contact Us       CPT Codes      Print Page    

NEUROLOGICAL PANEL

Tests included are: HD, SCA 1,2,3,6 & 7, DRPLA and FRDA

Gene Symbols: HTT, ATN1, FXN, ATXN 1,2,3,7

Chromosomal Locus: See individual tests

Pseudonyms: Ataxia, Neuromuscular

TURNAROUND TIME: 15 days

 TESTING METHODOLOGY:

Different polymerase chain reactions (PCR) that brackets the trinucleotide repeat regions. See individual test pages for more details.

SPECIMEN REQUIREMENTS:

  • Collect: Prefer two 5ml whole blood EDTA (lavender top) tube.
  • Min. Collection: 0.7 ml whole blood EDTA.
  • Transport: Blood EDTA at Room Temp shipped regular next day air (No Saturday delivery; store specimen at 4°C and ship Monday).
  • Stability: Ambient: up to 7 days; Refrigerated: 2 weeks. Frozen: unacceptable
  • Unacceptable Conditions: Serum. Frozen or severely hemolyzed blood. Clotted blood.

Prenatal testing: Direct: 5ml direct unspun amniotic fluid or 3mm3 CVS tissue with a backup flask growing. Culture: confluent T25 flask. Maternal blood sample is required for maternal cell contamination studies.

A Molecular Genetics Laboratory Test Requisition must accompany the specimen. Contact the Molecular Laboratory at 918-502-1721 to obtain further information.

Note: Counseling and informed consent are recommended for genetic testing. A consent form is available as a resource.

INTERPRETATIVE DATA:

Incidence: Unknown, perhaps about 1 in 10,000.

Inheritance: Mostly autosomal dominant. Variable age of onset but complete penetrance.

Disease Characteristics:

See details on individual sheets

Molecular Genetic Mechanism: See details on individual sheets

Related Tests: SCA Panel, DRPLA, FRDA and HD

Clinical Sensitivity: 99%

Over 97% of ataxia conditions (by incidence) are encompassed by this panel.

Analytical Sensitivity: 99%

Test Limitations: This testing examines the trinucleotide repeat regions, exclusively. However, no other mechanism has been described for these conditions and the testing is considered diagnostic. Rare diagnostic errors can occur due to primer or probe site mutations or rare polymorphisms.

INDICATIONS FOR USE:

  • Individuals with a family history of ataxias who want to determine their true risk.
  • Families considering future medical and disability insurance needs.
  • Individuals at risk who wish prenatal diagnosis.
  • To determine whether individuals with an ataxia have one of these conditions
  • To differentiate individuals with the ataxias.

ADDITIONAL RESOURCES:

OMIM - see specific tests

GeneReviews: http://www.ncbi.nlm.nih.gov/books/NBK1138/